John Forbes

36.1k total citations · 9 hit papers
202 papers, 16.5k citations indexed

About

John Forbes is a scholar working on Cancer Research, Oncology and Genetics. According to data from OpenAlex, John Forbes has authored 202 papers receiving a total of 16.5k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Cancer Research, 70 papers in Oncology and 65 papers in Genetics. Recurrent topics in John Forbes's work include Breast Cancer Treatment Studies (79 papers), Estrogen and related hormone effects (62 papers) and Cancer Treatment and Pharmacology (22 papers). John Forbes is often cited by papers focused on Breast Cancer Treatment Studies (79 papers), Estrogen and related hormone effects (62 papers) and Cancer Treatment and Pharmacology (22 papers). John Forbes collaborates with scholars based in United Kingdom, Australia and United States. John Forbes's co-authors include Jack Cuzick, Anthony Howell, Mitch Dowsett, Ivana Šestak, Aman U. Buzdar, Alan S. Coates, Michael Baum, Aron Goldhirsch, Beat Thürlimann and Richard D. Gelber and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Investigation.

In The Last Decade

John Forbes

197 papers receiving 15.9k citations

Hit Papers

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Com... 2003 2026 2010 2018 2005 2010 2007 2003 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    2005 1.7k citations Anthony Howell, Jack Cuzick et al. profile →
  2. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
    2010 1.1k citations Jack Cuzick, Ivana Šestak et al. The Lancet Oncology profile →
  3. Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
    2007 693 citations Alan S. Coates, Aparna Keshaviah et al. Journal of Clinical Oncology profile →
  4. Overview of the main outcomes in breast-cancer prevention trials
    2003 691 citations Jack Cuzick, John Forbes et al. profile →
  5. Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
    2009 581 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →
  6. Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
    2010 546 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →
  7. Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
    2011 540 citations Jack Cuzick, Mitch Dowsett et al. Journal of Clinical Oncology profile →
  8. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy
    2010 402 citations Andrew W. Bradbury, Donald J. Adam et al. Journal of Vascular Surgery profile →
  9. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
    2016 378 citations Marco Colleoni, Zhuoxin Sun et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Forbes United Kingdom 59 8.2k 6.7k 5.9k 3.2k 2.1k 202 16.5k
Victor G. Vogel United States 49 8.0k 1.0× 5.5k 0.8× 6.7k 1.1× 1.9k 0.6× 2.4k 1.1× 173 16.1k
James N. Atkins United States 47 8.3k 1.0× 4.4k 0.6× 3.9k 0.6× 3.8k 1.2× 2.6k 1.2× 107 14.4k
Michael Baum United Kingdom 53 6.3k 0.8× 5.8k 0.9× 3.5k 0.6× 2.5k 0.8× 2.2k 1.0× 283 13.3k
R. Jakesz Austria 58 7.2k 0.9× 5.2k 0.8× 3.0k 0.5× 2.2k 0.7× 2.3k 1.1× 337 12.2k
Beat Thürlimann Switzerland 57 10.9k 1.3× 10.1k 1.5× 5.5k 0.9× 3.4k 1.1× 2.9k 1.4× 214 17.9k
Patrick Neven Belgium 57 8.6k 1.1× 4.5k 0.7× 3.1k 0.5× 5.0k 1.6× 2.8k 1.3× 493 15.7k
Alan S. Coates Australia 76 14.4k 1.8× 11.0k 1.6× 4.9k 0.8× 4.3k 1.3× 3.7k 1.7× 297 23.6k
Judith M. Bliss United Kingdom 56 6.9k 0.8× 5.0k 0.7× 1.9k 0.3× 3.3k 1.0× 1.6k 0.7× 281 13.8k
Paul D.P. Pharoah United Kingdom 71 6.7k 0.8× 4.8k 0.7× 6.1k 1.0× 2.7k 0.8× 7.3k 3.4× 340 19.9k
Henning T. Mouridsen Denmark 57 8.0k 1.0× 6.7k 1.0× 2.5k 0.4× 3.6k 1.1× 1.6k 0.7× 243 14.1k

Countries citing papers authored by John Forbes

Since Specialization
Citations

This map shows the geographic impact of John Forbes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Forbes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Forbes more than expected).

Fields of papers citing papers by John Forbes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Forbes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Forbes. The network helps show where John Forbes may publish in the future.

Co-authorship network of co-authors of John Forbes

This figure shows the co-authorship network connecting the top 25 collaborators of John Forbes. A scholar is included among the top collaborators of John Forbes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Forbes. John Forbes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hunter, Andrew, Jane Walsh, Julie Bernhardt, et al.. (2024). Perspectives of People with Stroke, Caregivers and Healthcare Professionals on an Adaptive mHealth Intervention for Physical Activity in the Prevention of Secondary Stroke: A Qualitative Study. Journal of Multidisciplinary Healthcare. Volume 17. 2677–2688.
3.
Kennedy, Norelee, et al.. (2023). Stakeholder Perceptions of the Acceptability of Peer-Mediated Intervention for Minimally Speaking Preschoolers on the Autism Spectrum. Journal of Autism and Developmental Disorders. 54(5). 1774–1791. 1 indexed citations
4.
Anderson, Jana, Frederick K. Ho, Claire L. Niedzwiedz, et al.. (2021). Remote history of VTE is associated with severe COVID‐19 in middle and older age: UK Biobank cohort study. Journal of Thrombosis and Haemostasis. 19(10). 2533–2538. 4 indexed citations
5.
Hayes, Sara, John Forbes, Carlos Celis‐Morales, et al.. (2020). Association Between Walking Pace and Stroke Incidence. Stroke. 51(5). 1388–1395. 13 indexed citations
6.
Mangion, Kenneth, Philip D Adamson, Michelle C. Williams, et al.. (2019). Sex associations and computed tomography coronary angiography-guided management in patients with stable chest pain. European Heart Journal. 41(13). 1337–1345. 23 indexed citations
7.
Adamson, Philip D, Amanda Hunter, Anoop Shah, et al.. (2018). High-Sensitivity Cardiac Troponin I and the Diagnosis of Coronary Artery Disease in Patients With Suspected Angina Pectoris. Circulation Cardiovascular Quality and Outcomes. 11(2). e004227–e004227. 33 indexed citations
8.
9.
Afentakis, Maria, Mitch Dowsett, Ivana Šestak, et al.. (2013). Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Research and Treatment. 140(2). 253–262. 12 indexed citations
10.
Bhopal, Raj, Anne Douglas, Sunita Wallia, et al.. (2013). Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trial. The Lancet Diabetes & Endocrinology. 2(3). 218–227. 114 indexed citations
11.
Ewertz, Marianne, Kathryn P. Gray, Meredith M. Regan, et al.. (2012). Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. Journal of Clinical Oncology. 30(32). 3967–3975. 102 indexed citations
12.
Cuzick, Jack, Mitch Dowsett, Sílvia Pineda, et al.. (2011). Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. Journal of Clinical Oncology. 29(32). 4273–4278. 540 indexed citations breakdown →
13.
Dowsett, Mitch, Janine Salter, Lila Zabaglo, et al.. (2011). Predictive algorithms for adjuvant therapy: TransATAC. Steroids. 76(8). 777–780. 26 indexed citations
14.
Ring, Alistair, Ivana Šestak, Michael Baum, et al.. (2011). Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. Journal of Clinical Oncology. 29(32). 4266–4272. 50 indexed citations
15.
Handel, Ian, Mark Bronsvoort, John Forbes, & Mark Woolhouse. (2011). Risk-Targeted Selection of Agricultural Holdings for Post-Epidemic Surveillance: Estimation of Efficiency Gains. PLoS ONE. 6(5). e20064–e20064. 2 indexed citations
16.
17.
Dowsett, Mitch, Jack Cuzick, J. N. Ingle, et al.. (2009). Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. Journal of Clinical Oncology. 28(3). 509–518. 581 indexed citations breakdown →
18.
Mouridsen, Henning T., Aparna Keshaviah, Alan S. Coates, et al.. (2007). Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. Journal of Clinical Oncology. 25(36). 5715–5722. 93 indexed citations
19.
Mauriac, L., Aparna Keshaviah, Marc Debled, et al.. (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of Oncology. 18(5). 859–867. 106 indexed citations
20.
Keating, J. F., Adrian Grant, M. Masson, Neil Scott, & John Forbes. (2005). Displaced intracapsular hip fractures in fit, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty. Health Technology Assessment. 9(41). iii–iv, ix. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victor G. Vogel Breakdown of academic impact, for papers by James N. Atkins Breakdown of academic impact, for papers by Michael Baum Breakdown of academic impact, for papers by R. Jakesz Breakdown of academic impact, for papers by Beat Thürlimann Breakdown of academic impact, for papers by Patrick Neven Breakdown of academic impact, for papers by Alan S. Coates Breakdown of academic impact, for papers by Judith M. Bliss Breakdown of academic impact, for papers by Paul D.P. Pharoah Breakdown of academic impact, for papers by Henning T. Mouridsen
Rankless by CCL
2026